Cas 1350356-06-7,tert-butyl 3-(2-amino-5-methylphenylcarbamoyl)azetidine-1-carboxylate

1350356-06-7

Post Buying Request

Basic information

Product Name: tert-butyl 3-(2-amino-5-methylphenylcarbamoyl)azetidine-1-carboxylate
Synonyms: tert-butyl 3-(2-amino-5-methylphenylcarbamoyl)azetidine-1-carboxylate
CAS NO:1350356-06-7
Molecular Formula:
Molecular Weight: 305.377
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: tert-butyl 3-(2-amino-5-methylphenylcarbamoyl)azetidine-1-carboxylate(CAS DataBase Reference)
NIST Chemistry Reference: tert-butyl 3-(2-amino-5-methylphenylcarbamoyl)azetidine-1-carboxylate(1350356-06-7)
EPA Substance Registry System: tert-butyl 3-(2-amino-5-methylphenylcarbamoyl)azetidine-1-carboxylate(1350356-06-7)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1350356-06-7(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1350356-06-7 Suppliers

Recommended suppliers

1350356-06-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1350356-06-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,0,3,5 and 6 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1350356-06:
(9*1)+(8*3)+(7*5)+(6*0)+(5*3)+(4*5)+(3*6)+(2*0)+(1*6)=127
127 % 10 = 7
So 1350356-06-7 is a valid CAS Registry Number.

1350356-06-7Upstream product

1350356-06-7Downstream Products

1350356-06-7Relevant academic research and scientific papers

NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

-

Page/Page column 47-48, (2011/12/02)

Aryl- and heteroaryl-nitrogen heterocyclic compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDEIO, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1350356-06-7